|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9548
|
|
pubmed:dateCreated |
2006-11-13
|
|
pubmed:abstractText |
Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
11
|
|
pubmed:volume |
368
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1660-72
|
|
pubmed:dateRevised |
2008-4-1
|
|
pubmed:meshHeading |
pubmed-meshheading:17098084-Adolescent,
pubmed-meshheading:17098084-Adult,
pubmed-meshheading:17098084-Aged,
pubmed-meshheading:17098084-Blood Glucose,
pubmed-meshheading:17098084-Diabetes Mellitus, Type 2,
pubmed-meshheading:17098084-Dose-Response Relationship, Drug,
pubmed-meshheading:17098084-Double-Blind Method,
pubmed-meshheading:17098084-Drug Tolerance,
pubmed-meshheading:17098084-Female,
pubmed-meshheading:17098084-Hemoglobin A, Glycosylated,
pubmed-meshheading:17098084-Humans,
pubmed-meshheading:17098084-Male,
pubmed-meshheading:17098084-Middle Aged,
pubmed-meshheading:17098084-Obesity,
pubmed-meshheading:17098084-Overweight,
pubmed-meshheading:17098084-Patient Satisfaction,
pubmed-meshheading:17098084-Piperidines,
pubmed-meshheading:17098084-Pyrazoles,
pubmed-meshheading:17098084-Receptors, Cannabinoid,
pubmed-meshheading:17098084-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
|
|
pubmed:affiliation |
Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium. andre.scheen@chu.ulg.ac.be
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
